Literature DB >> 2838985

Strategy for construction of live picornavirus vaccines.

A Nomoto1, N Iizuka, M Kohara, M Arita.   

Abstract

A number of recombinant viruses between the virulent Mahoney and the attenuated Sabin 1 strains of type 1 poliovirus were constructed in vitro using their infectious cDNA clones. Monkey neurovirulence tests on these recombinant viruses revealed that the surface structure of the virion particle had a little correlation with the neurovirulent phenotype, and that the strong neurovirulence determinant(s) resided in the 5' noncoding sequence. These results in turn led to two possible strategies for constructing live attenuated picornavirus strains. One is to use the Sabin 1 strain as a vector carrying foreign antigenicities. The other is the construction of the attenuated picornaviruses by introducing mutations into the 5' noncoding sequences. The antigenicity of the Sabin 1 strain was successfully changed to those of other poliovirus serotypes without loss of vaccine quality. Furthermore, it was proved that introduction of deletion mutation into the 5' noncoding sequence of genomes of the Sabin 1 and Mahoney strains resulted in construction of viruses with a less neurovirulent phenotype.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2838985     DOI: 10.1016/s0264-410x(88)80015-x

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  9 in total

1.  Nucleotide sequences important for translation initiation of enterovirus RNA.

Authors:  N Iizuka; H Yonekawa; A Nomoto
Journal:  J Virol       Date:  1991-09       Impact factor: 5.103

2.  Construction of less neurovirulent polioviruses by introducing deletions into the 5' noncoding sequence of the genome.

Authors:  N Iizuka; M Kohara; K Hagino-Yamagishi; S Abe; T Komatsu; K Tago; M Arita; A Nomoto
Journal:  J Virol       Date:  1989-12       Impact factor: 5.103

3.  Determinants in the 5' noncoding region of poliovirus Sabin 1 RNA that influence the attenuation phenotype.

Authors:  N Kawamura; M Kohara; S Abe; T Komatsu; K Tago; M Arita; A Nomoto
Journal:  J Virol       Date:  1989-03       Impact factor: 5.103

4.  Genetic variation occurring on the genome of an in vitro insertion mutant of poliovirus type 1.

Authors:  S Kuge; N Kawamura; A Nomoto
Journal:  J Virol       Date:  1989-03       Impact factor: 5.103

5.  Protection against lethal encephalomyocarditis virus infection in the absence of serum-neutralizing antibodies.

Authors:  Z C Neal; G A Splitter
Journal:  J Virol       Date:  1998-10       Impact factor: 5.103

6.  Virus-host coevolution in a persistently coxsackievirus B3-infected cardiomyocyte cell line.

Authors:  Sandra Pinkert; Karin Klingel; Vanessa Lindig; Andrea Dörner; Heinz Zeichhardt; O Brad Spiller; Henry Fechner
Journal:  J Virol       Date:  2011-10-05       Impact factor: 5.103

7.  Myeloma xenograft destruction by a nonviral vector delivering oncolytic infectious nucleic acid.

Authors:  Elizabeth M Hadac; Elizabeth J Kelly; Stephen J Russell
Journal:  Mol Ther       Date:  2011-04-19       Impact factor: 11.454

8.  Picornavirus-specific CD4+ T lymphocytes possessing cytolytic activity confer protection in the absence of prophylactic antibodies.

Authors:  Z C Neal; G A Splitter
Journal:  J Virol       Date:  1995-08       Impact factor: 5.103

9.  Identification of mutations that occurred on the genome of Japanese encephalitis virus during the attenuation process.

Authors:  S Aihara; C M Rao; Y X Yu; T Lee; K Watanabe; T Komiya; H Sumiyoshi; H Hashimoto; A Nomoto
Journal:  Virus Genes       Date:  1991-04       Impact factor: 2.332

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.